NYSE · Healthcare
Emergent BioSolutions Inc. (EBS)
As-reported financials and recent SEC filings for Emergent BioSolutions Inc., latest fiscal period FY2025. Every figure is pulled straight from the company’s EDGAR filings — no estimates.
Snapshot
Revenue
$742.9M
Net income
$52.6M
Net margin
7.1%
Diluted EPS
$0.93
ROE
10.1%
P/E (TTM)
9.2×
Market cap
$440.1M
Debt / equity
1.1×
Income statement (as reported)
| Line | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 |
|---|---|---|---|---|---|
| Revenue | $742.9M | $1.04B | $1.05B | $1.12B | $1.77B |
| Gross profit | $416.7M | $362.3M | $343.9M | $424.4M | $1.03B |
| Operating income | $100.1M | $-108.7M | $-726.4M | $-170.0M | $341.4M |
| Net income | $52.6M | $-190.6M | $-760.5M | $-211.6M | $219.5M |
| Diluted EPS | $0.93 | $-3.60 | $-14.85 | $-4.22 | $4.06 |
Source: company XBRL financial statements on SEC EDGAR.
Recent SEC filings
42026-06-10
View on EDGAR →42026-06-10
View on EDGAR →42026-06-10
View on EDGAR →42026-06-10
View on EDGAR →42026-05-04
View on EDGAR →42026-05-04
View on EDGAR →42026-05-04
View on EDGAR →42026-05-04
View on EDGAR →Go deeper on EBS
Search Emergent BioSolutions Inc.’s filings with cited answers, compare it against peers, build an operating model, and track it in your portfolio — all in one place.
Start freeData sourced from SEC EDGAR (public domain). Figures are as-reported and may be unaudited or restated; verify against the source filing before relying on them. Informational only — not investment advice.